Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Immunol.

Sec. Microbial Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1620545

Immune-Modulating Therapy with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Refractory Rhino-Orbital-Cerebral Mucormycosis – a case report

Provisionally accepted
Jan-Alexis  TremblayJan-Alexis Tremblay1*Piremiya  ThayananthamPiremiya Thayanantham2Evan  Kalin-HajduEvan Kalin-Hajdu1Simon  DufresneSimon Dufresne1Julien-Viau  LapointeJulien-Viau Lapointe1
  • 1Hôpital Maisonneuve-Rosemont, Montreal, Canada
  • 2Université de Montréal, Montreal, Canada

The final, formatted version of the article will be published soon.

This report outlines the case of a woman with rhino-orbital-cerebral mucormycosis following diabetic ketoacidosis, refractory to systemic and local antifungal treatment as well as repeated extensive sinonasal debridement. Adjunctive Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) therapy was associated with significant clinical improvement. This treatment restored visual acuity, and the excellent outcomes were maintained at the 24-month follow-up. This is the first report of successful use of a short course (5 days) of GM-CSF for refractory rhino-orbital cerebral mucormycosis in an adult patient after diabetic ketoacidosis, highlighting the therapeutic potential of this pragmatic approach.

Keywords: Mucormycosis, GM-CSF, Immunomodulation, Mucorales, case report

Received: 29 Apr 2025; Accepted: 29 Aug 2025.

Copyright: © 2025 Tremblay, Thayanantham, Kalin-Hajdu, Dufresne and Lapointe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jan-Alexis Tremblay, Hôpital Maisonneuve-Rosemont, Montreal, Canada

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.